Red blood cell (RBC) transfusion is a mainstay of treatment for individuals requiring surgery, with traumatic injury, undergoing chemotherapy and with anemia due to bone marrow failure or other medical conditions. Despite this, red cell transfusion has been associated with poorer outcome in many of these patient populations [Hebert, 1999, Villaneuva 2013]. As well, it is a costly treatment and the product is often in short supply due to demands in excess of donor availability. Utilization trends increase year over year on a provincial and national basis, and this is unlikely to change in light of our aging population.
For these reasons, there is interest at all levels of care to ensure that RBC transfusion is undertaken only when necessary; when no other reasonable treatment option is available. My current research focuses on assessing blood transfusion practices and adherence to current recommendations.
Striking emperipolesis in megakaryocytes of gray platelet syndrome Blood Eric McGinnis and Kate M. Chipperfield DOI: 10.1182/blood.2019000494 06/2019
Microparticle content of platelet concentrates is predicted by donor microparticles and is altered by production methods and stress. Maurer-Spurej E and Larsen R and Labrie A and Heaton A and Chipperfield K DOI: 10.1016/j.transci.2016.07.010 PubMed: 27470708 08/2016
Acquired peanut hypersensitivity following platelet transfusion. Ponnampalam A and Growe G and Loftus P and Chipperfield K and Bigham M DOI: 10.1111/tme.12148 PubMed: 25180861 12/2014
Should intraoperative cell-salvaged blood be used in patients with suspected or known malignancy? Trudeau JD and Waters T and Chipperfield K DOI: 10.1007/s12630-012-9781-x PubMed: 22996966 11/2012
Temporal trends in the treatment of severe traumatic hemorrhage. Heidary B and Bell N and Ngai JT and Simons RK and Chipperfield K and Hameed SM DOI: 10.1016/j.amjsurg.2011.12.012 PubMed: 22417848 05/2012
Erroneous automated optical platelet counts in 1-hour post-transfusion blood samples. Maurer-Spurej E and Pittendreigh C and Yakimec J and De Badyn MH and Chipperfield K DOI: 10.1111/j.1751-553x.2008.01097.x PubMed: 18752538 02/2010
Platelet quality measured with dynamic light scattering correlates with transfusion outcome in hematologic malignancies. Maurer-Spurej E and Labrie A and Pittendreigh C and Chipperfield K and Smith C and Heddle N and Liu Y and Yi QL and Barnett M DOI: 10.1111/j.1537-2995.2009.02302.x PubMed: 19903289 11/2009
Past and future approaches to assess the quality of platelets for transfusion. Maurer-Spurej E and Chipperfield K DOI: 10.1016/j.tmrv.2007.05.005 PubMed: 17900491 10/2007
Posttransplant diffuse large B-cell lymphoma of "lymphomatoid granulomatosis" type. Saxena A and Dyker KM and Angel S and Moshynska O and Dharampaul S and Cockroft DW DOI: 10.1007/s00428-002-0694-x PubMed: 12587601 12/2002
Current Project I am currently supervising a project to audit RBC transfusions administered across various hospitals in Greater Vancouver. We will gauge whether the transfusion was appropriate or inappropriate based on most current guidelines. The cumulative results of the audit will provide information to hospital Transfusion Medicine (TM) leaders, ordering clinicians, hospital executive and the Ministry of Health (MoH), and form a baseline for future RBC Utilization Management (UM) endeavors. This information will have the potential to influence quality outcomes for patients.
2010-2011. Canadian Blood Services Grant. (Co-PI with E. Maurer) Comparison of in vivo outcome following transfusion of dynamic light scattering screened versus unscreened platelets.
2011. VCH Quality and Patient Safety. Development of On-line tutorial - Appropriate TM Practice for MD’s.
2010-2014. Co DIVO RCT
A randomized controlled trial of high quality platelet concentrates as determined by ThromboLUX score versus standard of care platelets in patients with hematological malignancy.
Honours & Awards
Award for Excellence in Clinical Service, UBC Dept of Pathology and Laboratory Medicine, 2011.
Faculty of Medicine Clinical Excellence in Teaching Award, UBC. May 2007.
Human DNA testing could improve outcomes for patients with COVID-19.
That’s the key idea put forth in preliminary research posted this month to bioRxiv that highlights the potential benefits of testing COVID-19 patients for genetic variants of ACE2—the protein identified as the point-of-entry for the SARS-COV-2 virus into human cells.
Congratulations to the BC Children's and BC Women's investigators who were awarded funding through the highly competitive Canadian Institutes of Health Research (CIHR) Project Grant Fall 2019 competition.
A new study suggests that specialized immune cells that dampen inflammation and help repair the gut could be used as a potential therapy for children dealing with the painful symptoms of inflammatory bowel disease.
We believe there’s nothing we can’t do with your support. It can take years to turn scientific breakthrough into new interventions and treatments. Funding helps speed the pace of change. When given the resources, we can bring transformative therapies – and hope – out of the laboratory and into the clinic to save and improve children’s lives.